There are 2789 resources available
1205P - Treatment sequencing and duration of subsequent tyrosine kinase inhibitors in ALK+ non-small cell lung cancer patients treated with brigatinib in the US
Presenter: Mohammad Jahanzeb
Session: ePoster Display
1206P - UNcommon EGFR mutations: International Case series on efficacy of Osimertinib in Real-life practice in first-liNe setting (UNICORN)
Presenter: Jair Bar
Session: ePoster Display
1030TiP - An open-label multicenter phase Ib study of AN0025, a selective inhibitor of the prostaglandin E2 receptor-type-4 receptor, in combination with pembrolizumab in patients with advanced solid tumors
Presenter: Wallace Akerley
Session: ePoster Display
Resources:
Abstract
1031TiP - Vascular intervention combined with camrelizumab and apatinib for patients with inoperable solid tumors: An exploratory study
Presenter: Feng Gao
Session: ePoster Display
1033TiP - A first-in-human phase I study of FS120, an OX40/CD137 tetravalent bispecific antibody, in patients with advanced malignancies
Presenter: Kyriakos Papadopoulos
Session: ePoster Display
1085P - Ph I/II study of PI3K-β inhibitor GSK2636771 (G771) in combination with pembrolizumab (P) in patients (pts) with PTEN loss and melanoma or other advanced solid tumors
Presenter: Elizabeth Burton
Session: ePoster Display
1086P - IBI310 alone or in combination with sintilimab for advanced melanoma: Updated results of a phase Ia/Ib study
Presenter: BIN LIAN
Session: ePoster Display
1087P - The importance of anti-PD-1 dosing in the treatment of patients with inoperable or metastatic melanoma
Presenter: Bozena Cybulska-Stopa
Session: ePoster Display